These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9341639)

  • 21. Antithrombotic treatment before and after peripheral artery percutaneous angioplasty.
    Visonà A; Tonello D; Zalunardo B; Irsara S; Liessi G; Marigo L; Zotta L
    Blood Transfus; 2009 Jan; 7(1):18-23. PubMed ID: 19290075
    [No Abstract]   [Full Text] [Related]  

  • 22. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
    Klootwijk P; Meij S; Melkert R; Lenderink T; Simoons ML
    Circulation; 1998 Oct; 98(14):1358-64. PubMed ID: 9760288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antithrombotic therapy during percutaneous coronary interventions].
    Verheugt FW; Dieker H; Aengevaeren WR
    Ned Tijdschr Geneeskd; 2005 Apr; 149(17):912-6. PubMed ID: 15884403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Popma JJ; Berger P; Ohman EM; Harrington RA; Grines C; Weitz JI
    Chest; 2004 Sep; 126(3 Suppl):576S-599S. PubMed ID: 15383485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
    Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
    Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
    [No Abstract]   [Full Text] [Related]  

  • 28. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
    Tselepis AD; Goudevenos JA; Tambaki AP; Michalis L; Stroumbis CS; Tsoukatos DC; Elisaf M; Sideris DA
    Cardiovasc Res; 1999 Jul; 43(1):183-91. PubMed ID: 10536703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abciximab in the treatment of ST-segment elevation myocardial infarction.
    Tan DS; Sim DK; Chan ES; Tan RS
    JAMA; 2005 Oct; 294(14):1760-1; author reply 1761. PubMed ID: 16219877
    [No Abstract]   [Full Text] [Related]  

  • 30. Contemporary diagnosis and management of unstable angina.
    Reeder GS
    Mayo Clin Proc; 2000 Sep; 75(9):953-7. PubMed ID: 10994831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?].
    Cimminiello C; Soncini M; Casazza F
    G Ital Cardiol; 1995 Sep; 25(9):1187-93. PubMed ID: 8529856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antithrombotic agents in unstable angina. Review of clinical trials].
    Habis M; Morice MC
    Ann Cardiol Angeiol (Paris); 1998 Jan; 47(1):22-31. PubMed ID: 9772929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition.
    Califf RM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S33-7. PubMed ID: 10650314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tirofiban in unstable coronary disease.
    Liron M
    N Engl J Med; 1998 Oct; 339(16):1163-5. PubMed ID: 9776651
    [No Abstract]   [Full Text] [Related]  

  • 36. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.
    Dunn CJ; Foster RH
    Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New thrombocyte aggregation inhibitor in therapy of unstable angina].
    Hamm C
    Z Kardiol; 2000 Nov; 89(11):1053-6. PubMed ID: 11149273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial.
    Cannon CP
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):43S-48S. PubMed ID: 12644340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
    Juran NB
    Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T; McGavin JK; Goa KL
    Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.